Maclary Shawn C, Mohanty Sambit K, Bose Shikha, Chung Fai, Balzer Bonnie L
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):144-149. doi: 10.1097/PAI.0000000000000277.
In the United States, it is estimated that 100,000 people are living with metastatic breast cancer (BC) with bone representing the most common site of involvement. However, patients with isolated bone metastasis at presentation may have a longer survival. Therapeutic options for BC bone metastases often include systemic anticancer therapy (endocrine, chemotherapy, monoclonal antibodies, and/or other targeted therapies), which is largely dependent on the immunohistochemical (IHC) repertoire of the cancer for the prognostic markers [estrogen (ER) and progesterone receptors (PR), Ki-67, p53, and Her-2/neu] at its osseous metastatic site. Traditionally, specimens obtained from the bone metastasis require decalcification, which may affect the immunoreactivity of these prognostic markers. To the best of our knowledge, limited studies describe the effect of decalcification on immunoexpression of the above-mentioned markers. A detailed illustration of the effect of decalcification on BC specimens in a real-time manner is lacking in the literature.
Herein, we sought to determine the impact of decalcification on the IHC expression pattern of the above listed markers on BC tissue following decalcification.
After Institutional Review Board approval, sections from the residual tumor specimens were collected prospectively from 15 BC excision specimens and 1 curetting from a BC bone metastasis. The sections (3 to 6 sections/case) for decalcification were collected following routine submission for pathologic evaluation. The sections were subjected to hydrochloric acid (HCl)-based Decal Stat decalcifying solution for 2, 12, 18, and 24 hours in each case. IHC studies for ER, PR, Ki-67, p53, and Her-2/neu were performed on 1 representative section of the regularly processed tumor block and 1 decalcified tumor block from each time point. Scoring of ER and PR were performed according to the Allred scoring system. Scoring of Her-2/neu was performed according to CAP/ASCO guidelines.
The tumors comprised 11 grade 3 invasive ductal carcinomas, 2 grade 2 invasive ductal carcinomas, 2 grade 3 invasive lobular carcinoma, and 1 metastatic BC to bone. Nine cases showed Allred score 8 for ER, 1 case showed Allred score 4, 1 case showed Allred score 2, and the remaining 5 were ER negative. For PR, 1 showed Allred score 8, 2 Allred score 7, 4 Allred score 6, 1 each Allred score 5 and score 2 with the remainder negative for PR. Ki-67 ranged from 5% to 95%. Five cases showed p53 overexpression ranging from 35% to 95%. Five cases each showed 3+, 6 cases showed 2+ Her-2/neu, 3 cases showed 1+ Her-2/neu, and the remaining 2 were negative. All specimens demonstrated decline in ER, PR, Ki-67, and p53 immunoreactivity after 2 hours of decalcification, with additional decline up to 24 hours. The most significant declines in immunoreactivity occurred with Ki-67 and p53. Most of the Her-2/neu cases with an equivocal score declined to zero after 24 hours of decalcification. However, 3 out of 11 cases showing Her-2/neu overexpression remained at the baseline scoring even after extended (24 h) decalcification.
Our results demonstrated that the decalcification process affects the immunoreactivity of the prognostic BC markers. There is progressive loss of reactivity at 2 hours and beyond for markers with lower degrees of expression. In addition, heterogeneity in marker distribution progressed from diffuse to more focal beyond 1 hour.
在美国,据估计有10万人患有转移性乳腺癌(BC),其中骨骼是最常见的受累部位。然而,初诊时仅有骨转移的患者可能生存期更长。BC骨转移的治疗选择通常包括全身抗癌治疗(内分泌治疗、化疗、单克隆抗体和/或其他靶向治疗),这在很大程度上取决于骨转移部位癌症的免疫组化(IHC)检测结果,以确定预后标志物[雌激素(ER)和孕激素受体(PR)、Ki-67、p53和Her-2/neu]。传统上,从骨转移灶获取的标本需要脱钙,这可能会影响这些预后标志物的免疫反应性。据我们所知,关于脱钙对上述标志物免疫表达影响的研究有限。文献中缺乏对BC标本脱钙效果的实时详细说明。
在此,我们试图确定脱钙对脱钙后BC组织中上述标志物IHC表达模式的影响。
经机构审查委员会批准后,前瞻性地从15例BC切除标本的残留肿瘤标本和1例BC骨转移刮除标本中收集切片。脱钙切片(每例3至6片)在常规送检病理评估后收集。每例切片分别用基于盐酸(HCl)的Decal Stat脱钙液处理2、12、18和24小时。对每个时间点常规处理的肿瘤蜡块和脱钙肿瘤蜡块的1个代表性切片进行ER、PR、Ki-67、p53和Her-2/neu的IHC研究。ER和PR评分按照Allred评分系统进行。Her-2/neu评分按照CAP/ASCO指南进行。
肿瘤包括11例3级浸润性导管癌、2例2级浸润性导管癌、2例3级浸润性小叶癌和1例骨转移BC。9例ER的Allred评分为8分,1例为4分,1例为2分,其余5例ER阴性。PR方面,1例Allred评分为8分,2例为7分,4例为6分,1例为5分,1例为2分,其余PR阴性。Ki-67范围为5%至95%。5例p53过表达,范围为35%至95%。5例Her-2/neu为3+,6例为2+,3例为1+,其余2例为阴性。所有标本在脱钙2小时后ER、PR、Ki-67和p53的免疫反应性均下降,直至24小时仍持续下降。免疫反应性下降最显著的是Ki-67和p53。大多数Her-2/neu评分不明确的病例在脱钙24小时后降至零分。然而,11例Her-2/neu过表达的病例中有3例即使在延长(24小时)脱钙后仍保持基线评分。
我们的结果表明,脱钙过程会影响BC预后标志物的免疫反应性。对于表达程度较低的标志物,在2小时及以后反应性会逐渐丧失。此外,标志物分布的异质性在1小时后从弥漫性发展为更局灶性。